ERBB2 and breast cancer: Thus, these studies along with our data strongly support the notion that the tumor cells of the HER2-positive overexpressed metastatic breast cancer patients who relapsed after (neo)adjuvant trastuzumab treatment may still be sensitive to trastuzumab and that trastuzumab re-treatment is an important therapy for these patients.